news paper icon

Analyzed News

Novartis gains U.S. approval for delayed MS drug

ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. [Source]

Publication Date:

Origin: reuters.com

Category: healthNews

Topics: approval, drug, glatopa, larger, division

Source Link: http://feeds.reuters.com/~r/reuters/healthNews/~3/B2EPYIvAHcE/novartis-gains-u-s-approval-for-delayed-ms-drug-idUSKBN1FX0LY

Related Articles